menu
    • menu
    [{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ethyl Icosapentate","moa":"Cell membrane \/ PPARs","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mochida Pharmaceutical \/ Sumitomo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Mochida Pharmaceutical \/ Sumitomo Pharma"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Desvenlafaxine Succinate","moa":"Norepinephrine transporter | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mochida Pharmaceutical \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Mochida Pharmaceutical \/ Pfizer Inc"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Mochida Pharmaceutical \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Mochida Pharmaceutical \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"EA Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Macrogol","moa":"PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Mochida Pharmaceutical \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Mochida Pharmaceutical \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"Prostaglandin G\/H synthase (COX)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mochida Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mochida Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"Prostaglandin G\/H synthase (COX)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mochida Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mochida Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Fuji Yakuhin","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mochida Pharmaceutical \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Mochida Pharmaceutical \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Fuji Yakuhin","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mochida Pharmaceutical \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Mochida Pharmaceutical \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Fuji Yakuhin","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mochida Pharmaceutical \/ Fuji Yakuhin","highestDevelopmentStatusID":"10","companyTruncated":"Mochida Pharmaceutical \/ Fuji Yakuhin"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Fuji Yakuhin","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mochida Pharmaceutical \/ Fuji Yakuhin","highestDevelopmentStatusID":"6","companyTruncated":"Mochida Pharmaceutical \/ Fuji Yakuhin"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Fuji Yakuhin","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mochida Pharmaceutical \/ Fuji Yakuhin","highestDevelopmentStatusID":"10","companyTruncated":"Mochida Pharmaceutical \/ Fuji Yakuhin"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Fuji Yakuhin","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mochida Pharmaceutical \/ Fuji Yakuhin","highestDevelopmentStatusID":"6","companyTruncated":"Mochida Pharmaceutical \/ Fuji Yakuhin"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Fuji Yakuhin","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mochida Pharmaceutical \/ Fuji Yakuhin","highestDevelopmentStatusID":"6","companyTruncated":"Mochida Pharmaceutical \/ Fuji Yakuhin"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"LG Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mochida Pharmaceutical \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Mochida Pharmaceutical \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"LG Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mochida Pharmaceutical \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Mochida Pharmaceutical \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Fuji Yakuhin","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Radiolabeled Compound","year":"2016","type":"Inapplicable","leadProduct":"14-C FYU-981","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mochida Pharmaceutical \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Mochida Pharmaceutical \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Epa-E","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mochida Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mochida Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mochida Pharmaceutical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Mochida Pharmaceutical

    Menu

    Mochida Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daridorexant

                            Therapeutic Area : Sleep

                            Study Phase : Approved FDF

                            Recipient : Idorsia Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Idorsia Japan Announces Positive Results With Daridorexant In A Phase 3 Study Of Japanese Patients With Insomn...

                            Details : The study met both primary and secondary efficacy endpoint measures ACT-541468 (Daridorexant) significantly improved sTST from baseline compared to placebo at 28 days (p<0.001 for 50 mg, p=0.042 for 25 mg).

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            October 03, 2022

                            Lead Product(s) : Daridorexant

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved FDF

                            Recipient : Idorsia Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macrogol

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Recipient : EA Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            “MOVICOL® HD” Launched - A New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment fo...

                            Details : MOVICOL® HD is a high dose formulation of existing “MOVICOL® LD”, the first polyethylene glycol indicated for treatment of chronic constipation1) in Japan. MOVICOL® HD contains the same active ingredients in double the quantity of MOVICOL® LD per...

                            Product Name : Movicol HD

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 20, 2022

                            Lead Product(s) : Macrogol

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Recipient : EA Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Desvenlafaxine Succinate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of MD-120 in Patients With Depression

                            Details : Desvenlafaxine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 14, 2020

                            Lead Product(s) : Desvenlafaxine Succinate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ethyl Icosapentate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Sumitomo Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia

                            Details : Ethyl Icosapentate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertriglyceridemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 27, 2020

                            Lead Product(s) : Ethyl Icosapentate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Sumitomo Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia

                            Details : Icosapent is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertriglyceridemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 09, 2020

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of MND-2119 in Participants With Hypertriglyceridemia

                            Details : Icosapent is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertriglyceridemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 02, 2018

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I

                            Sponsor : Fuji Yakuhin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)

                            Details : FYU-981 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hyperuricemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 18, 2017

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I

                            Sponsor : Fuji Yakuhin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase III

                            Sponsor : Fuji Yakuhin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

                            Details : FYU-981 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperuricemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 13, 2017

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase III

                            Sponsor : Fuji Yakuhin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Fuji Yakuhin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Pharmacology of FYU-981 (Final Formulation)

                            Details : FYU-981 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 22, 2017

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Fuji Yakuhin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mochida Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Fuji Yakuhin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug-drug Interaction Study of FYU-981 and Oxaprozin

                            Details : FYU-981 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 22, 2017

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Fuji Yakuhin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth